Difference in Impact of CYP2C19 Polymorphism on Platelet Reactivity and Clinical Outcomes Between Acute Coronary Syndrome (ACS) and Stable Angina

被引：0
|
作者：
Hokimoto, Seiji [1 ]
Akasaka, Tomonori [1 ]
Kaikita, Koichi [1 ]
Nakagawa, Kazuko [2 ]
Ogawa, Hisao [1 ]
机构：
[1] Kumamoto Univ, Dept Cardiovasc Med, Kumamoto, Japan
[2] Kumamoto Univ, Div Pharmacol & Therapeut, Kumamoto, Japan
来源：
CIRCULATION | 2013年 / 128卷 / 22期
关键词：
Acute coronary syndromes; Pharmacogenetics; Percutaneous coronary intervention; Genetics;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
16546
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation
    Tabata, Noriaki
    Hokimoto, Seiji
    Akasaka, Tomonori
    Arima, Yuichiro
    Kaikita, Koichi
    Kumagae, Naoki
    Morita, Kazunori
    Miyazaki, Hiroko
    Oniki, Kentaro
    Nakagawa, Kazuko
    Matsui, Kunihiko
    Ogawa, Hisao
    THROMBOSIS RESEARCH, 2014, 134 (05) : 939 - 944
  • [32] Chronic Kidney Disease Status Modifies the Association of CYP2C19 Polymorphism in Predicting Clinical Outcomes Following Coronary Stent Implantation
    Tabata, Noriaki
    Hokimoto, Seiji
    Akasaka, Tomonori
    Arima, Yuichiro
    Kaikita, Koichi
    Nakagawa, Kazuko
    Ogawa, Hisao
    CIRCULATION, 2014, 130
  • [33] Perspective on CYP2C19 genotyping test among patients with acute coronary syndrome - a qualitative study
    Png, Wan Yu
    Wong, Xin Yi
    Kwan, Yu Heng
    Lin, Ying Ying
    Tan, Doreen Su-Yin
    FUTURE CARDIOLOGY, 2020, 16 (06) : 655 - 662
  • [34] Gender Differences in Impact of Vascular Endothelial Dysfunction or CYP2C19 Polymorphism on Clinical Outcome Following Coronary Stenting in Patients with Coronary Heart Disease
    Hokimoto, Seiji
    Akasaka, Tmonori
    Tabata, Noriaki
    Arima, Yuichiro
    Kaikita, Koichi
    Nakagawa, Kazuko
    Ogawa, Hisao
    CIRCULATION, 2014, 130
  • [35] A synergic effect between CYP2C19∗2, CYP2C19∗3 loss-of-function and CYP2C19∗17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients
    Hassani Idrissi H.
    Hmimech W.
    Khorb N.E.
    Akoudad H.
    Habbal R.
    Nadifi S.
    BMC Research Notes, 11 (1)
  • [36] The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting
    Harmsze, Ankie M.
    van Werkum, Jochem W.
    Hackeng, Christian M.
    Ruven, Hendrik J. T.
    Kelder, Johannes C.
    Bouman, Heleen J.
    Breet, Nicoline J.
    ten Berg, Jurrien M.
    Klungel, Olaf H.
    de Boer, Anthonius
    Deneer, Vera H. M.
    PHARMACOGENETICS AND GENOMICS, 2012, 22 (03) : 169 - 175
  • [37] Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Lee, Craig R.
    Sriramoju, Vindhya B.
    Cervantes, Alexandra
    Howell, Lucius A.
    Varunok, Nicholas
    Madan, Shivanshu
    Hamrick, Kasey
    Polasek, Melissa J.
    Lee, John Andrew
    Clarke, Megan
    Cicci, Jonathan D.
    Weck, Karen E.
    Stouffer, George A.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (04): : e002069
  • [38] Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes
    Dong, Peng
    Yang, Xinchun
    Bian, Suyan
    MEDICAL SCIENCE MONITOR, 2016, 22 : 4929 - 4936
  • [39] Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors
    Tomek, Ales
    Mat'oska, Vaclav
    Frydmanova, Alena
    Magerova, Hana
    Sramek, Martin
    Paulasova-Schwabova, Jaroslava
    Ruzickova, Tereza
    Jansky, Petr
    Sarbochova, Ivana
    Hadacova, Ivana
    Kaplan, Vojtech
    Lacinova, Zuzana
    Taborsky, Ludek
    Serebruany, Victor
    AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (02) : E202 - E212
  • [40] Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients?
    van den Broek, Wout W. A.
    ten Berg, Jurrien M.
    PHARMACOGENOMICS, 2021, 22 (12) : 727 - 730
12345